303 related articles for article (PubMed ID: 25850435)
1. A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells.
Stuart SA; Houel S; Lee T; Wang N; Old WM; Ahn NG
Mol Cell Proteomics; 2015 Jun; 14(6):1599-615. PubMed ID: 25850435
[TBL] [Abstract][Full Text] [Related]
2. Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition.
Shi H; Kong X; Ribas A; Lo RS
Cancer Res; 2011 Aug; 71(15):5067-74. PubMed ID: 21803746
[TBL] [Abstract][Full Text] [Related]
3. Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance.
Shi H; Moriceau G; Kong X; Lee MK; Lee H; Koya RC; Ng C; Chodon T; Scolyer RA; Dahlman KB; Sosman JA; Kefford RF; Long GV; Nelson SF; Ribas A; Lo RS
Nat Commun; 2012 Mar; 3():724. PubMed ID: 22395615
[TBL] [Abstract][Full Text] [Related]
4. MEK-independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720.
Jiang CC; Lai F; Thorne RF; Yang F; Liu H; Hersey P; Zhang XD
Clin Cancer Res; 2011 Feb; 17(4):721-30. PubMed ID: 21088259
[TBL] [Abstract][Full Text] [Related]
5. Novel ATP-competitive MEK inhibitor E6201 is effective against vemurafenib-resistant melanoma harboring the MEK1-C121S mutation in a preclinical model.
Narita Y; Okamoto K; Kawada MI; Takase K; Minoshima Y; Kodama K; Iwata M; Miyamoto N; Sawada K
Mol Cancer Ther; 2014 Apr; 13(4):823-32. PubMed ID: 24448821
[TBL] [Abstract][Full Text] [Related]
6. The Akt inhibitor MK2206 synergizes, but perifosine antagonizes, the BRAF(V600E) inhibitor PLX4032 and the MEK1/2 inhibitor AZD6244 in the inhibition of thyroid cancer cells.
Liu R; Liu D; Xing M
J Clin Endocrinol Metab; 2012 Feb; 97(2):E173-82. PubMed ID: 22090271
[TBL] [Abstract][Full Text] [Related]
7. The MEK1/2 inhibitor AS703026 circumvents resistance to the BRAF inhibitor PLX4032 in human malignant melanoma cells.
Park SJ; Hong SW; Moon JH; Jin DH; Kim JS; Lee CK; Kim KP; Hong YS; Choi EK; Lee JS; Lee JL; Kim TW
Am J Med Sci; 2013 Dec; 346(6):494-8. PubMed ID: 24051957
[TBL] [Abstract][Full Text] [Related]
8. Adaptive upregulation of FOXD3 and resistance to PLX4032/4720-induced cell death in mutant B-RAF melanoma cells.
Basile KJ; Abel EV; Aplin AE
Oncogene; 2012 May; 31(19):2471-9. PubMed ID: 21996740
[TBL] [Abstract][Full Text] [Related]
9. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
[TBL] [Abstract][Full Text] [Related]
10. The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations.
Comin-Anduix B; Chodon T; Sazegar H; Matsunaga D; Mock S; Jalil J; Escuin-Ordinas H; Chmielowski B; Koya RC; Ribas A
Clin Cancer Res; 2010 Dec; 16(24):6040-8. PubMed ID: 21169256
[TBL] [Abstract][Full Text] [Related]
11. Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032.
Vergani E; Vallacchi V; Frigerio S; Deho P; Mondellini P; Perego P; Cassinelli G; Lanzi C; Testi MA; Rivoltini L; Bongarzone I; Rodolfo M
Neoplasia; 2011 Dec; 13(12):1132-42. PubMed ID: 22241959
[TBL] [Abstract][Full Text] [Related]
12. Evaluating melanoma drug response and therapeutic escape with quantitative proteomics.
Rebecca VW; Wood E; Fedorenko IV; Paraiso KH; Haarberg HE; Chen Y; Xiang Y; Sarnaik A; Gibney GT; Sondak VK; Koomen JM; Smalley KS
Mol Cell Proteomics; 2014 Jul; 13(7):1844-54. PubMed ID: 24760959
[TBL] [Abstract][Full Text] [Related]
13. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
[TBL] [Abstract][Full Text] [Related]
14. Time-resolved Phosphoproteome Analysis of Paradoxical RAF Activation Reveals Novel Targets of ERK.
Kubiniok P; Lavoie H; Therrien M; Thibault P
Mol Cell Proteomics; 2017 Apr; 16(4):663-679. PubMed ID: 28188228
[TBL] [Abstract][Full Text] [Related]
15. Phosphoproteomics of MAPK inhibition in BRAF-mutated cells and a role for the lethal synergism of dual BRAF and CK2 inhibition.
Parker R; Clifton-Bligh R; Molloy MP
Mol Cancer Ther; 2014 Jul; 13(7):1894-906. PubMed ID: 24825855
[TBL] [Abstract][Full Text] [Related]
16. PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells.
Halaban R; Zhang W; Bacchiocchi A; Cheng E; Parisi F; Ariyan S; Krauthammer M; McCusker JP; Kluger Y; Sznol M
Pigment Cell Melanoma Res; 2010 Apr; 23(2):190-200. PubMed ID: 20149136
[TBL] [Abstract][Full Text] [Related]
17. Specificity of Phosphorylation Responses to Mitogen Activated Protein (MAP) Kinase Pathway Inhibitors in Melanoma Cells.
Basken J; Stuart SA; Kavran AJ; Lee T; Ebmeier CC; Old WM; Ahn NG
Mol Cell Proteomics; 2018 Apr; 17(4):550-564. PubMed ID: 29255136
[TBL] [Abstract][Full Text] [Related]
18. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.
Greger JG; Eastman SD; Zhang V; Bleam MR; Hughes AM; Smitheman KN; Dickerson SH; Laquerre SG; Liu L; Gilmer TM
Mol Cancer Ther; 2012 Apr; 11(4):909-20. PubMed ID: 22389471
[TBL] [Abstract][Full Text] [Related]
19. PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas.
Lee JT; Li L; Brafford PA; van den Eijnden M; Halloran MB; Sproesser K; Haass NK; Smalley KS; Tsai J; Bollag G; Herlyn M
Pigment Cell Melanoma Res; 2010 Dec; 23(6):820-7. PubMed ID: 20973932
[TBL] [Abstract][Full Text] [Related]
20. Docking-based structural splicing and reassembly strategy to develop novel deazapurine derivatives as potent B-Raf
Wang GM; Wang X; Zhu JM; Guo BB; Yang Z; Xu ZJ; Li B; Wang HY; Meng LH; Zhu WL; Ding J
Acta Pharmacol Sin; 2017 Jul; 38(7):1059-1068. PubMed ID: 28414204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
